Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Reforms Include ‘Prudent-Use’ Targets For Cuts To Antibiotic Consumption

Executive Summary

The European Commission says at least 65% of all human consumption of antibiotics should be of products that come under the World Health Organization’s AWaRe (Access, Watch, Reserve) classification, which have a lower risk of resistance.

You may also be interested in...



EU Pharma Revision: Legislators Prepare For Long-Haul Debate

The European Parliament and the Council of the EU are preparing their positions on the planned overhaul of the EU medicines legislation ahead of discussions that are expected to take two to three years.

AESGP Annual Meeting: OTC Antifungals, Antivirals Could Become Rx In EU

The European Commission shocked participants at this year's AESGP Annual Meeting by warning that OTC antifungals, like treatments for athlete’s foot, and OTC antivirals, like cold sore creams, could soon become prescription-only within the region, under proposed revisions to the EU pharma legislation. There is hope, however. The proposals are still open to feedback from industry, the AESGP points out, and even if this proposal becomes law, member states can waive this prescription requirement under certain conditions.

UK Offers Fresh Funding For New Drugs & Vaccines Against AMR

New funding from the UK’s antimicrobial resistance innovation fund is to be welcomed, but the UK pharmaceutical industry body, the ABPI, has cautioned that “multiple global solutions” bringing together governments, health care systems and the industry are needed if research efforts are to result in effective new antibiotics.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel